Results 21 to 30 of about 29,513 (309)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]

Hepatology, 2013
Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Aghemo, Alessio, De Francesco, Raffaele
openaire   +2 more sources

Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic Leukemia

Pediatric Hematology Oncology Journal, 2018
We report the unique case of a nine-month old patient diagnosed with B- Cell Acute Lymphoblastic Leukemia also positive for Hepatitis C virus, genotype 3 and a high viral load.
Qurratulain Shahood Ahmed, Zehra Fadoo, Kamran Sadiq, Sadaf Altaf   +3 more
doaj   +1 more source

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia, Romano, Antonietta, Russo, Francesco Paolo   +2 more
core   +1 more source

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

Case Reports in Gastroenterology, 2015
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +11 more
doaj   +1 more source

Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]

Farmacia Hospitalaria, 2016
Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis, Javier Saez de la Fuente, Ismael Escobar Rodriguez, Concepción Esteban Alba, Ana Such Díaz, Ismael Escobar Rodríguez   +5 more
doaj   +1 more source

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia, DE SANTIS, Adriano, GINANNI CORRADINI, Stefano, Lattanzi, Barbara, Lupo1, Marinella, Maria Galluzzo, Clementina, Mennini, Gianluca, Merli, Manuela, Michelini, Zuleika, Palmisano, Lucia, Rossi, Massimo   +10 more
core   +1 more source

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients

Nefrología (English Edition), 2017
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez   +9 more
doaj   +1 more source

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Farinati, Fabio, Ferrarese, Alberto, Forton, Dm, Franceschet, E, Gambato, M, Germani, Giacomo, Mescoli, Claudia, Romano, Antonietta, Rugge, Massimo, Russo, FRANCESCO PAOLO, Senzolo, Marco, Shalaby, S, Vitale, A, Zanetto, Alberto   +16 more
core   +1 more source

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications [PDF]

Clinical Pharmacokinetics, 2016
Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed since the development and licensing of new potent direct-acting antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes.
Smolders, E.J., Kanter, C.T., Knegt, R.J. de, Valk, M. van der, Drenth, J.P., Burger, D.M.   +5 more
core   +8 more sources